Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01481402

Acronym

LIHFA

Enrollment

Registered

2011-11-29

Start date

2011-07-31

Completion date

2014-02-28

Last updated

2019-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Low T3 Syndrome

Keywords

Heart failure, Liothyronine, Low T3 syndrome

Brief summary

Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.

Detailed description

The patients are examined 3 times. At baseline, after 3 months and after 6 months.After the examination is performed, they begin the study medication while admitted at Dept. of Cardiology, Herlev Hospital, for cardiac monitoring.

Interventions

DRUGLiothyronine

Liothyronine 40 microgram per day

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with stable, chronic systolic heart failure * T3 ≤1.4 nmol/l in two blood samples, TSH is to be normal * LVEF ≤ 45 % on prior echocardiography

Exclusion criteria

* Established thyroid illness * Atrial fibrillation/flutter * More than 20% ventricular extrasystoles * Severe chronic obstructive lung disorder * Pregnancy. Pregnancy testing will be done for fertile women * Age \< 18 years

Design outcomes

Primary

Measure	Time frame	Description
left ventricle ejection fraction	3 months	The effect of liothyronine treatment in low dose in 3 months on LVEF.

Secondary

Measure	Time frame	Description
Quality of Life, questionaire	3 months	The effect of 3 months low dose liothyronine treatment on quality of life, assessed by SF-36 and Minnesota Living with Heart Failure questionnaires in patients with heart failure.
YKL-40, YNF-alpha, hsCRP and IL-6	3 months	The effect of 3 months low dose liothyronine treatment on low grade inflammation assessed by measurement of pro-inflammatory markers in patients with heart failure.
Body composition	3 months	The effect of 3 months low dose liothyronine treatment on body composition in patients with heart failure.
GDF 8, SHBG, CK and PINP	3 months	The effect of 3 months low dose liothyronine treatment on the extrathyroidal thyroid effect in patients with heart failure.
NT-proBNP, EDV and ESV	3 months	The effect of 3 months low dose liothyronine treatment on heart function in patients with heart failure.
RBP 4, HBA1C, adiponectin (high and low weight), glucose and HOMA-1	3 months	The effect of 3 months low dose liothyronine treatment on metabolic status in patients with heart failure.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026